Compare GameStop Corp. (GME) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Merck & Co., Inc. — how do they compare? GameStop Corp. trades at $26.64 (market cap $12.75B), while Merck & Co., Inc. trades at $146.05 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 27.6× GameStop Corp.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Merck & Co., Inc. for 98 Days on average.
| GME | MRK | |
|---|---|---|
Market Cap | $12.75B | $351.28B |
Volume | 13,026,993 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $156.43 |
52-Week Low | $17.87 | $82.49 |
Typical Hold Time | 62 Days | 98 Days |
Enterprise Value | $12.03B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $26.56, up 8.06% over 24 hours, with a bullish technical signal supported by moving averages. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, while revenue declined to $3.82 billion. Strong insider buying by CEO Ryan Cohen and directors has fueled positive sentiment, though analyst consensus remains cautious with a majority hold rating.
The outlook for GME hinges on execution of its strategic pivot to high-margin collectibles and leveraging its $4.77 billion cash position. Key risks include revenue volatility, competitive pressures, and dependence on insider confidence. Upside potential exists if earnings growth sustains, but investors face uncertainty from inconsistent profitability and high valuation multiples relative to historical performance.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
